These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26473963)

  • 1. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses.
    Weger-Lucarelli J; Aliota MT; Kamlangdee A; Osorio JE
    PLoS Negl Trop Dis; 2015; 9(10):e0004163. PubMed ID: 26473963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
    Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
    J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
    Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
    J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
    Chua CL; Sam IC; Merits A; Chan YF
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
    Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
    J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.
    Fox JM; Long F; Edeling MA; Lin H; van Duijl-Richter MKS; Fong RH; Kahle KM; Smit JM; Jin J; Simmons G; Doranz BJ; Crowe JE; Fremont DH; Rossmann MG; Diamond MS
    Cell; 2015 Nov; 163(5):1095-1107. PubMed ID: 26553503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semliki Forest Virus Chimeras with Functional Replicase Modules from Related Alphaviruses Survive by Adaptive Mutations in Functionally Important Hot Spots.
    Teppor M; Žusinaite E; Karo-Astover L; Omler A; Rausalu K; Lulla V; Lulla A; Merits A
    J Virol; 2021 Sep; 95(20):e0097321. PubMed ID: 34319778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
    Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent envelope E2 alphavirus sequences spanning amino acids 297 to 352 induce in mice virus-specific protective immunity and antibodies with complement-mediated cytolytic activity.
    Grosfeld H; Lustig S; Gozes Y; Velan B; Cohen S; Leitner M; Lachmi B; Katz D; Olshevski U; Shafferman A
    J Virol; 1992 Feb; 66(2):1084-90. PubMed ID: 1309890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
    Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
    J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
    Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
    PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
    Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
    PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
    Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
    Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
    J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.